Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care

This article was originally published in The Pink Sheet Daily

Executive Summary

Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.
Advertisement

Related Content

Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma IPOs Start To Gear Up For 2013 After A Lull
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Hoping Drugs Take Root, Alder Raises $38 Million Round
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder
Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder

Topics

Advertisement
UsernamePublicRestriction

Register

PS072397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel